Skip to main content
  • Home
  •  ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma

ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma

Topic:
  • Prevention

Available Credit:

  • Not accredited

Course Published On:

Course Expiry Date:

Overview

Prof Subodh Verma (University of Toronto, Toronto, CA) discusses his poster presented at the ACC 2019 entitled duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide - a post hoc analysis of the LEADER and SUSTAIN-6 Clinical Trials.

Target Audience

  • Cardiologists 
  • Diabetologists
  • Nephrologists 
This course is not accredited

Related Courses

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
  • 2.00 EBAC

Learning objectives

  • Describe the burden of ASCVD in type 2 diabetes
  • Assign risk of future CV events to individuals with type 2 diabetes
  • Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
  • Recall trial data of anti-diabetes medications that reduce ASCVD risk
  • Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
  • Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
  • Adopt anti-diabetic therapies with proven ASCVD benefit
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more